Estimated population-level impact of pneumococcal conjugate vaccines against all-cause pneumonia mortality among unvaccinated age groups in five Latin American countries

Ottavia Prunas,Kayoko Shioda,Cristiana M Toscano,Magdalena Bastias,Maria Teresa Valenzuela-Bravo,Janepsy Diaz Tito,Joshua L Warren,Daniel M Weinberger,Lucia H de Oliveira

DOI: https://doi.org/10.1093/infdis/jiae144

2024-03-21

The Journal of Infectious Diseases

Abstract:Pneumococcal conjugate vaccines (PCVs) provide strong direct protection in children, while limited data are available on their indirect effect on mortality among older age groups. This multi-country study aimed to assess the population-level impact of pediatric PCVs on all-cause pneumonia mortality among ≥5 years of age, and invasive pneumococcal disease (IPD) cases in Chile. Demographic and mortality data from Argentina, Brazil, Chile, Colombia, and Mexico were collected considering the ≥ 5-year-old population, from 2000-2019, with 1,795,789 deaths due to all-cause pneumonia. IPD cases in Chile were also evaluated. Time series models were employed to evaluate changes in all-cause pneumonia deaths during the post-vaccination period, with other causes of death used as synthetic controls for unrelated temporal trends. No significant change in death rates due to all-cause pneumonia was detected following PCV introduction among most age groups and countries. The proportion of IPD cases caused by vaccine serotypes decreased from 29% (2012) to 6% (2022) among ≥65 years in Chile. While an effect of PCV against pneumonia deaths (a broad clinical definition that may not be specific enough to measure indirect effects) was not detected, evidence of indirect PCV impact was observed among vaccine-type-specific IPD cases.

immunology,infectious diseases,microbiology

What problem does this paper attempt to address?

This paper aims to evaluate the overall impact of pneumococcal conjugate vaccines (PCVs) on all - cause pneumonia mortality in unvaccinated people aged ≥5 years in five Latin American countries, as well as the impact on invasive pneumococcal disease (IPD) cases in Chile. The research background points out that although PCVs provide a strong direct protective effect in children, there are limited data on their indirect effects on mortality in the elderly population. Therefore, the goal of this multi - country study is to evaluate the indirect protective effect of pediatric PCVs in people aged ≥5 years by analyzing population - level data.

Specifically, the study attempts to answer the following questions:
1. **The impact of PCVs on all - cause pneumonia mortality in people aged ≥5 years**: The study used population death data from Argentina, Brazil, Chile, Colombia and Mexico, covering the period from 2000 to 2019, with a total of 1,795,789 all - cause pneumonia death cases recorded. The change in all - cause pneumonia mortality after the introduction of PCVs was evaluated using a time - series model.
2. **The impact of PCVs on IPD cases in people aged ≥65 years in Chile**: The study also evaluated the change in the proportion of IPD cases caused by vaccine serotypes in people aged ≥65 years in Chile.

Research methods include using the synthetic control (SC) model, the interrupted time - series (ITS) model, and the SC + ITS model that combines these two methods to reduce bias and isolate the impact of PCVs on all - cause pneumonia mortality. These methods quantify the effect of PCVs by comparing the observed mortality rate with the expected mortality rate in the absence of PCV introduction.

The main results show that in most countries and age groups, the all - cause pneumonia mortality rate has not changed significantly after the introduction of PCVs. However, some changes have been observed in certain age groups and countries. For example, the all - cause pneumonia mortality rate has decreased in the 5 - 19 - year - old and 20 - 39 - year - old age groups in Brazil, while the mortality rate has increased in the 40 - 64 - year - old age group in Mexico and the ≥80 - year - old age group in Argentina. In addition, the proportion of IPD cases caused by vaccine serotypes in people aged ≥65 years in Chile has decreased from 29% in 2012 to 6% in 2022, indicating the indirect protective effect of PCVs.

Overall, this study provides important insights into the impact of PCVs on all - cause pneumonia mortality and IPD cases in unvaccinated people in Latin American countries, highlighting the importance of data quality and analytical methods in evaluating vaccine effectiveness.